MBA-m1

• Description :

  MBA-m1 is a MLKL inhibitor. MBA-m1 inhibits necroptosis in Mlkl−/− NIH-3T3 cells. MBA-m1 ameliorates disease in MLKL-induced dermatitis and abdominal aortic aneurysm mouse model[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Mixed Lineage Kinase

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Purity :

  95.71

• Smiles :

  ClC1=CC(NC2=CC(C)=NC3=C2C=C(OC)C=C3)=CC=C1OC4=CC5=C(C=CC=C5)C=C4

• Molecular Formula :

  C27H21ClN2O2

• Molecular Weight :

  440.92

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ros U, et al. MLKL activity requires a splicing-regulated, druggable intramolecular interaction. Mol Cell. 2025 Apr 17;85 (8) :1589-1605.e12.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound2

• Clinical Information :

  No Development Reported

• CAS Number :

  [305866-70-0]